Study on SLC46A1: Potential Drug Target and Biomarker for Various Diseases

Target Name: SLC46A1

NCBI ID: G113235

SLC46A1

Study on SLC46A1: Potential Drug Target and Biomarker for Various Diseases

SLC46A1 (hPCFT), a gene located on chromosome 16, has been identified as a potential drug target and biomarker for various diseases, including cancer. Its function and regulation have been extensively studied, providing insights into the underlying mechanisms of these diseases.

SLC46A1 is a gene that encodes a protein known as hPCFT, which stands for holographic fragment complement. This protein plays a critical role in the regulation of mitochondrial function, energy metabolism, and stress responses. It is a key player in the mitochondrial dynamics and is involved in various cellular processes that are essential for human health and disease.

Mitochondria are organelles that are responsible for generating energy for the cell through a process called cellular respiration. They are also involved in the production of reactive oxygen species (ROS), which can cause damage to cellular components and contribute to various diseases, including cancer. Therefore, the regulation of mitochondrial function is crucial for the maintenance of cellular homeostasis and the prevention of oxidative stress-induced diseases.

SLC46A1 is involved in the regulation of mitochondrial fusion, which is the process by which mitochondria fuse with each other to form a single mitochondrial fission complex. Fusion is a critical process for maintaining cellular energy homeostasis and for the production of ATP, the primary source of cellular energy.

SLC46A1 is also involved in the regulation of mitochondrial fission, which is the process by which mitochondria divide into two daughter mitochondria. Fission is a critical process for the growth and development of cells and is regulated by various factors, including the availability of oxygen and the levels of reactive oxygen species.

In addition to its role in mitochondrial function, SLC46A1 is also involved in the regulation of cellular stress responses. Stress responses are critical for the survival of cells under various conditions, including stress, starvation, and radiation. SLC46A1 is involved in the regulation of cellular stress through the production of stress-responsive signaling pathways, which are essential for the regulation of cellular stress responses.

SLC46A1 has also been identified as a potential drug target for various diseases, including cancer. Cancer is a disease that is characterized by the formation of tumors, which can be treated with various therapeutic approaches, including drugs that target specific proteins involved in the disease. SLC46A1 is a potential drug target because of its involvement in cellular stress responses and its role in the regulation of mitochondrial function.

SLC46A1 has been shown to be involved in various cellular stress responses, including the regulation of cellular DNA damage repair, the production of reactive oxygen species, and the regulation of cellular signaling pathways. These processes are critical for the development and progression of cancer, and targeting SLC46A1 with drugs that can inhibit its function may be an effective strategy for the treatment of cancer.

In addition to its potential as a drug target, SLC46A1 is also considered as a biomarker for various diseases, including cancer. The levels of hPCFT in cells can be used as a marker for the diagnosis and monitoring of cancer, as well as for the evaluation of the effectiveness of anti-cancer therapies.

SLC46A1 is a gene that has been extensively studied for its involvement in cellular stress responses and its potential as a drug target and biomarker for various diseases. Its function and regulation have been extensively studied, providing insights into the underlying mechanisms of these diseases. Further research is needed to fully understand the role of SLC46A1 in cellular stress responses and its potential as a drug target and biomarker.

Protein Name: Solute Carrier Family 46 Member 1

Functions: Proton-coupled folate symporter that mediates folate absorption using an H(+) gradient as a driving force (PubMed:17129779, PubMed:17446347, PubMed:17475902, PubMed:19389703, PubMed:19762432, PubMed:25504888, PubMed:30858177, PubMed:31792273, PubMed:34619546, PubMed:29344585, PubMed:31494288, PubMed:32893190). Involved in the intestinal absorption of folates at the brush-border membrane of the proximal jejunum, and the transport from blood to cerebrospinal fluid across the choroid plexus (PubMed:17129779, PubMed:17446347, PubMed:17475902, PubMed:19389703, PubMed:25504888, PubMed:30858177, PubMed:29344585, PubMed:31494288, PubMed:32893190). Functions at acidic pH via alternate outward- and inward-open conformation states (PubMed:34040256, PubMed:32893190). Protonation of residues in the outward open state primes the protein for transport (PubMed:34040256). Binding of folate promotes breaking of salt bridge network and subsequent closure of the extracellular gate, leading to the inward-open state and release of protons and folate (PubMed:34040256). Also able to transport antifolate drugs, such as methotrexate and pemetrexed, which are established treatments for cancer and autoimmune diseases (PubMed:18524888, PubMed:19762432, PubMed:25608532, PubMed:28802835, PubMed:29326243, PubMed:34619546, PubMed:34040256, PubMed:22345511). Involved in FOLR1-mediated endocytosis by serving as a route of export of folates from acidified endosomes (PubMed:19074442). Also acts as a lower-affinity, pH-independent heme carrier protein and constitutes the main importer of heme in the intestine (PubMed:17156779). Imports heme in the retina and retinal pigment epithelium, in neurons of the hippocampus, in hepatocytes and in the renal epithelial cells (PubMed:32621820). Hence, participates in the trafficking of heme and increases intracellular iron content (PubMed:32621820)

The "SLC46A1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC46A1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets